- Home
- RGC vs PGEN Comparison
RGC vs PGEN Comparison
Compare RGC & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- PGEN
- Stock Information
- Founded
- RGC 2014
- PGEN 1998
- Country
- RGC Hong Kong
- PGEN United States
- Employees
- RGC N/A
- PGEN N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- RGC Health Care
- PGEN Health Care
- Exchange
- RGC Nasdaq
- PGEN Nasdaq
- Market Cap
- RGC 377.5M
- PGEN 404.4M
- IPO Year
- RGC 2021
- PGEN N/A
- Fundamental
- Price
- RGC $38.01
- PGEN $1.45
- Analyst Decision
- RGC
- PGEN Strong Buy
- Analyst Count
- RGC 0
- PGEN 3
- Target Price
- RGC N/A
- PGEN $6.00
- AVG Volume (30 Days)
- RGC 1.5M
- PGEN 1.6M
- Earning Date
- RGC 07-01-2025
- PGEN 08-13-2025
- Dividend Yield
- RGC N/A
- PGEN N/A
- EPS Growth
- RGC N/A
- PGEN N/A
- EPS
- RGC N/A
- PGEN N/A
- Revenue
- RGC N/A
- PGEN $4,201,000.00
- Revenue This Year
- RGC N/A
- PGEN $158.57
- Revenue Next Year
- RGC N/A
- PGEN $1,086.91
- P/E Ratio
- RGC N/A
- PGEN N/A
- Revenue Growth
- RGC N/A
- PGEN N/A
- 52 Week Low
- RGC $0.08
- PGEN $0.65
- 52 Week High
- RGC $83.60
- PGEN $2.17
- Technical
- Relative Strength Index (RSI)
- RGC 56.71
- PGEN 53.70
- Support Level
- RGC $15.12
- PGEN $1.47
- Resistance Level
- RGC $83.60
- PGEN $1.59
- Average True Range (ATR)
- RGC 10.44
- PGEN 0.11
- MACD
- RGC 3.76
- PGEN 0.01
- Stochastic Oscillator
- RGC 34.05
- PGEN 63.64
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.